NEW YORK, Sept. 20 (GenomeWeb News) - Iconix Pharmaceuticals said today that it has signed an agreement to work with Roderick Jensen, acting director of the biotechnology center and laboratory for functional genomics at the Brigham and Women's Hospital, on the study and validation of gene expression patterns in patients with neurological diseases.
According to Iconix, Jensen's lab has developed a high-throughput validation strategy that uses multiple gene expression platforms to assay tissue samples. The partnership aims to validate gene expression changes in human peripheral blood for diagnostics, prognostics, and drug response. Jensen's strategy, Iconix said, will be tested in patients with Parkinson's disease.
In March, at the 43rd Annual Society of Toxicology Meeting in Baltimore, Md., Iconix said that it would publicly release a subset of its proprietary genomic biomarker data to researchers who agree to make their findings public.